Advertisement Genzyme appoints David Meeker as new CEO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Genzyme appoints David Meeker as new CEO

Genzyme, a subsidiary of Sanofi, has appointed David Meeker as the new Chief Executive Officer, with effect from 1 November.

Genzyme will incorporate the Rare Disease business and the Multiple Sclerosis franchise, under the leadership of the new CEO, the company said.

David joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program.

He has been the president of the Global Rare Disease Business and looked into the global launches of Aldurazyme, Fabrazyme and Myozyme.

In 2009, David became the Chief Operating Officer of Genzyme.

Sanofi CEO Christopher A Viehbacher said David Meeker’s combination of medical and business experience will drive Genzyme’s range of products forward and help in the delivery of therapies.

Sanofi focuses on discovery, development and distribution of therapeutic solutions with special emphasis on diabetes solutions, human vaccines, innovative drugs, rare diseases and consumer healthcare.